Schizophrenia in the elderly: Guidelines for management

Martha Sajatovic, Subramoniam Madhusoodanan, Peter Buckley

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The treatment of schizophrenia in older populations poses special challenges for patients, family members and clinicians. These include changes in manifestation of schizophrenic illness in later life, age-related changes in response to pharmacological treatments and psychosocial issues associated with older life status. As with younger individuals, antipsychotic medications constitute the mainstay of treatment for schizophrenia in the elderly. However, the drug treatment of schizophrenia is substantially affected by the aging process. Medication sensitivity is pronounced in the elderly, largely due to age-related changes in the body's capacity to metabolise psychotropic and other drugs. Other relevant factors include higher rates of physical comorbidity, drug-drug interactions and age-related adverse effects. Generally, the appropriate starting dose of antipsychotic medication in the elderly is 25% of the adult dose. Total daily maintenance doses may be 30 to 50% of the adult dose. The use of conventional antipsychotics in the elderly is limited because of their association with extrapyramidal symptoms and anticholinergic and cardiovascular adverse effects. The advent of atypical antipsychotics has revolutionised the treatment of psychosis in the elderly. Based on the general psychiatric literature, the atypical agents have been found to be as efficacious as conventional agents in reducing positive symptoms, more efficacious against negative symptoms, and to have a much more benign adverse effect profile. Nonpharmacological issues in the management of schizophrenia in the elderly are at least as important as in younger individuals. Older individuals may face additional challenges that affect health outcome, such as living alone or being unable to drive. All drug treatments should be partnered with supportive approaches and psychosocial interventions that maximise treatment compliance and improve outcome.

Original languageEnglish (US)
Pages (from-to)103-115
Number of pages13
JournalCNS Drugs
Volume13
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Schizophrenia
Guidelines
Antipsychotic Agents
Therapeutics
Pharmaceutical Preparations
Psychotropic Drugs
Reducing Agents
Cholinergic Antagonists
Drug Interactions
Psychotic Disorders
Psychiatry
Comorbidity
Pharmacology
Health
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Sajatovic, M., Madhusoodanan, S., & Buckley, P. (2000). Schizophrenia in the elderly: Guidelines for management. CNS Drugs, 13(2), 103-115. https://doi.org/10.2165/00023210-200013020-00004

Schizophrenia in the elderly : Guidelines for management. / Sajatovic, Martha; Madhusoodanan, Subramoniam; Buckley, Peter.

In: CNS Drugs, Vol. 13, No. 2, 01.01.2000, p. 103-115.

Research output: Contribution to journalArticle

Sajatovic, M, Madhusoodanan, S & Buckley, P 2000, 'Schizophrenia in the elderly: Guidelines for management', CNS Drugs, vol. 13, no. 2, pp. 103-115. https://doi.org/10.2165/00023210-200013020-00004
Sajatovic, Martha ; Madhusoodanan, Subramoniam ; Buckley, Peter. / Schizophrenia in the elderly : Guidelines for management. In: CNS Drugs. 2000 ; Vol. 13, No. 2. pp. 103-115.
@article{498a01d984464137ae1552184a9c1091,
title = "Schizophrenia in the elderly: Guidelines for management",
abstract = "The treatment of schizophrenia in older populations poses special challenges for patients, family members and clinicians. These include changes in manifestation of schizophrenic illness in later life, age-related changes in response to pharmacological treatments and psychosocial issues associated with older life status. As with younger individuals, antipsychotic medications constitute the mainstay of treatment for schizophrenia in the elderly. However, the drug treatment of schizophrenia is substantially affected by the aging process. Medication sensitivity is pronounced in the elderly, largely due to age-related changes in the body's capacity to metabolise psychotropic and other drugs. Other relevant factors include higher rates of physical comorbidity, drug-drug interactions and age-related adverse effects. Generally, the appropriate starting dose of antipsychotic medication in the elderly is 25{\%} of the adult dose. Total daily maintenance doses may be 30 to 50{\%} of the adult dose. The use of conventional antipsychotics in the elderly is limited because of their association with extrapyramidal symptoms and anticholinergic and cardiovascular adverse effects. The advent of atypical antipsychotics has revolutionised the treatment of psychosis in the elderly. Based on the general psychiatric literature, the atypical agents have been found to be as efficacious as conventional agents in reducing positive symptoms, more efficacious against negative symptoms, and to have a much more benign adverse effect profile. Nonpharmacological issues in the management of schizophrenia in the elderly are at least as important as in younger individuals. Older individuals may face additional challenges that affect health outcome, such as living alone or being unable to drive. All drug treatments should be partnered with supportive approaches and psychosocial interventions that maximise treatment compliance and improve outcome.",
author = "Martha Sajatovic and Subramoniam Madhusoodanan and Peter Buckley",
year = "2000",
month = "1",
day = "1",
doi = "10.2165/00023210-200013020-00004",
language = "English (US)",
volume = "13",
pages = "103--115",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Schizophrenia in the elderly

T2 - Guidelines for management

AU - Sajatovic, Martha

AU - Madhusoodanan, Subramoniam

AU - Buckley, Peter

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The treatment of schizophrenia in older populations poses special challenges for patients, family members and clinicians. These include changes in manifestation of schizophrenic illness in later life, age-related changes in response to pharmacological treatments and psychosocial issues associated with older life status. As with younger individuals, antipsychotic medications constitute the mainstay of treatment for schizophrenia in the elderly. However, the drug treatment of schizophrenia is substantially affected by the aging process. Medication sensitivity is pronounced in the elderly, largely due to age-related changes in the body's capacity to metabolise psychotropic and other drugs. Other relevant factors include higher rates of physical comorbidity, drug-drug interactions and age-related adverse effects. Generally, the appropriate starting dose of antipsychotic medication in the elderly is 25% of the adult dose. Total daily maintenance doses may be 30 to 50% of the adult dose. The use of conventional antipsychotics in the elderly is limited because of their association with extrapyramidal symptoms and anticholinergic and cardiovascular adverse effects. The advent of atypical antipsychotics has revolutionised the treatment of psychosis in the elderly. Based on the general psychiatric literature, the atypical agents have been found to be as efficacious as conventional agents in reducing positive symptoms, more efficacious against negative symptoms, and to have a much more benign adverse effect profile. Nonpharmacological issues in the management of schizophrenia in the elderly are at least as important as in younger individuals. Older individuals may face additional challenges that affect health outcome, such as living alone or being unable to drive. All drug treatments should be partnered with supportive approaches and psychosocial interventions that maximise treatment compliance and improve outcome.

AB - The treatment of schizophrenia in older populations poses special challenges for patients, family members and clinicians. These include changes in manifestation of schizophrenic illness in later life, age-related changes in response to pharmacological treatments and psychosocial issues associated with older life status. As with younger individuals, antipsychotic medications constitute the mainstay of treatment for schizophrenia in the elderly. However, the drug treatment of schizophrenia is substantially affected by the aging process. Medication sensitivity is pronounced in the elderly, largely due to age-related changes in the body's capacity to metabolise psychotropic and other drugs. Other relevant factors include higher rates of physical comorbidity, drug-drug interactions and age-related adverse effects. Generally, the appropriate starting dose of antipsychotic medication in the elderly is 25% of the adult dose. Total daily maintenance doses may be 30 to 50% of the adult dose. The use of conventional antipsychotics in the elderly is limited because of their association with extrapyramidal symptoms and anticholinergic and cardiovascular adverse effects. The advent of atypical antipsychotics has revolutionised the treatment of psychosis in the elderly. Based on the general psychiatric literature, the atypical agents have been found to be as efficacious as conventional agents in reducing positive symptoms, more efficacious against negative symptoms, and to have a much more benign adverse effect profile. Nonpharmacological issues in the management of schizophrenia in the elderly are at least as important as in younger individuals. Older individuals may face additional challenges that affect health outcome, such as living alone or being unable to drive. All drug treatments should be partnered with supportive approaches and psychosocial interventions that maximise treatment compliance and improve outcome.

UR - http://www.scopus.com/inward/record.url?scp=0034104293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034104293&partnerID=8YFLogxK

U2 - 10.2165/00023210-200013020-00004

DO - 10.2165/00023210-200013020-00004

M3 - Article

AN - SCOPUS:0034104293

VL - 13

SP - 103

EP - 115

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -